Biolight (BOLT) AI Stock Analysis

• Market Cap: ₪29.86M
• Dividend Yield: N/A
• Average Volume (3M): 11.86K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.65
• Revenue Growth: -46.97%
• EPS Growth: -127.67%
• Country: IL
• Employees: 4
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 9,047,603
• 10 Day Avg. Volume: 7,448
• 30 Day Avg. Volume: 11,863
• PEG Ratio: 0.05
• Price to Book (P/B): 0.96
• Price to Sales (P/S): 117.59
• P/FCF Ratio: -2.34
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: 366.00 ▼(-1.45% Downside)
• Action: Reiterated Date: 12/12/25
• Date: Action: Reiterated 12/12/25

Biolight's overall stock score is primarily impacted by its financial performance, which is hindered by negative profitability and cash flow challenges. The technical analysis indicates a bearish trend, and the valuation is weak due to a negative P/E ratio. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Low Debt-to-Equity Ratio

A low debt-to-equity ratio suggests Biolight has conservative leverage, providing financial stability and flexibility for future investments.

Revenue Growth

Revenue growth indicates Biolight's ability to expand its market presence and product adoption, supporting long-term business sustainability.

Positive Free Cash Flow Growth

Positive free cash flow growth suggests Biolight is improving its cash generation, which is crucial for funding operations and future growth initiatives.

Negative Factors

Negative Profitability

Negative profitability highlights ongoing financial struggles, which can hinder Biolight's ability to invest in R&D and sustain operations long-term.

High Operating Losses

High operating losses indicate inefficiencies in cost management, impacting Biolight's ability to achieve sustainable profitability and competitive positioning.

Negative Cash Flows

Negative cash flows reflect operational inefficiencies and can limit Biolight's capacity to fund growth initiatives and meet financial obligations.

Biolight Business Overview & Revenue Model

Company Description

BioLight Life Sciences Ltd., an ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions. The company's ophthalmic product offering and pipeline of product candidates include DiagnosTear's TeaRx technology, a diagnostic platform for diagnosis of disease in the frontal areas of the eye through examination of a number of substances in the composition of teardrops; ViSci, an Eye D technology that treats glaucoma by the insertion of a sub conjunctival implant; OphRx that develops drugs for treating eye diseases; and Peripherex, which develops solutions for at-home and in-office diagnosis and monitoring of peripheral vision impairment used by eye care and other providers to diagnose and monitor glaucoma and other diseases. Its pipeline also include AEYE that develops artificial intelligence solutions for a variety of retinal diseases; Tarsier, which develops TRS 01 based on its technological platform for the treatment of Uveitis in patients suffering from high IPO; Belkin Vision that develops clinic fast and automatic laser device to enable glaucoma patients to receive short & effective treatments as treatment to lower IOP; and Sanoculis, which develops an innovative surgical procedure for the treatment of the Glaucoma. The company was formerly known as Bio Light Israeli Life Sciences Investments Ltd. and changed its name to BioLight Life Sciences Ltd. in February 2016. BioLight Life Sciences Ltd. was incorporated in 2005 and is based in Tel Aviv, Israel.

How the Company Makes Money

Biolight generates revenue through multiple streams, primarily by selling its proprietary medical devices and biopharmaceutical products to healthcare providers, hospitals, and clinics. The company also engages in contract research and development services for pharmaceutical companies, providing expertise in the development of new therapies. Key revenue streams include direct product sales, licensing agreements for its technology, and partnerships with larger pharmaceutical firms that seek to leverage Biolight's innovative solutions. Additionally, government grants and funding for research initiatives contribute to the company's financial stability, allowing it to reinvest in further innovation and product development.

Biolight Financial Statement Overview

Summary

Biolight faces significant financial challenges, with negative profitability and cash flows despite revenue growth. The low debt-to-equity ratio is a positive, but the negative returns on equity and high operating losses are concerning.

Income Statement

Biolight's revenue has shown some growth, with a 10.6% increase in the latest year. However, the company is struggling with profitability, as indicated by negative net profit and EBIT margins. The gross profit margin remains positive, but the high operating losses suggest significant challenges in cost management and achieving sustainable profitability.

Balance Sheet

The company maintains a low debt-to-equity ratio, indicating conservative leverage. However, the return on equity is negative, reflecting ongoing losses. The equity ratio is relatively stable, suggesting a solid asset base, but the inability to generate positive returns is a concern.

Cash Flow

Biolight's cash flow situation is challenging, with negative operating and free cash flows. The free cash flow growth is positive, but the operating cash flow to net income ratio indicates inefficiencies in converting income into cash. The company needs to improve cash generation to support operations and growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	219.00K	118.00K	63.00K	3.00K	31.00K
Gross Profit	-544.00K	219.00K	118.00K	63.00K	3.00K	31.00K
EBITDA	-14.66M	-7.75M	-10.60M	-8.03M	-1.31M	-10.84M
Net Income	-11.73M	-7.14M	-26.02M	-7.85M	382.00K	-13.38M
Balance Sheet
Total Assets	42.41M	34.12M	33.45M	57.01M	64.17M	64.83M
Cash, Cash Equivalents and Short-Term Investments	23.65M	13.47M	8.64M	17.63M	33.71M	49.95M
Total Debt	772.00K	599.00K	91.00K	527.00K	443.00K	929.00K
Total Liabilities	2.24M	3.38M	3.15M	3.32M	2.75M	4.72M
Stockholders Equity	34.40M	26.88M	29.78M	53.17M	60.70M	59.22M
Cash Flow
Free Cash Flow	-10.86M	-11.02M	-10.99M	-9.64M	-10.65M	-13.49M
Operating Cash Flow	-10.85M	-10.99M	-9.58M	-9.54M	-10.03M	-11.39M
Investing Cash Flow	-16.17M	7.55M	-1.95M	-10.55M	13.48M	2.01M
Financing Cash Flow	21.37M	7.98M	3.25M	-485.00K	915.00K	4.77M

Biolight Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 371.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:BOLT, the sentiment is Neutral. The current price of 371.4 is above the 20-day moving average (MA) of 334.52, above the 50-day MA of 351.21, and below the 200-day MA of 434.71, indicating a neutral trend. The MACD of -4.48 indicates Negative momentum. The RSI at 50.32 is Neutral, neither overbought nor oversold. The STOCH value of 45.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IL:BOLT.

Biolight Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CANF	54 Neutral	₪23.20M	-4,037.78	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BLRX	46 Neutral	₪36.55M	-4.21	―	―	-42.69%	88.04%
PPBT	43 Neutral	₪18.58M	-0.13	―	―	―	89.32%
BOLT	42 Neutral	₪29.86M	-0.94	―	―	-46.97%	-127.67%